• NurExone’s U.S. subsidiary Exo-Top signed a binding MOU with ExoLyra for exclusive distribution of naïve MSC-derived exosomes in Mexico.
• Definitive agreement targeted within 45 days; Mexico exclusivity set at three years, extendable to 10 years subject to performance.
• ExoLyra to pay US$180,000 exclusivity fee; US$40,000 at signing, US$140,000 once products are ready to ship.
• Annual sales maintenance fee of US$100,000 starts in year 4; ExoLyra to fund market entry with at least US$800,000.
• Minimum purchases to keep exclusivity: 20,000 units in first 18 months, rising to 60,000 units from year 4 with 5% escalator.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief on June 24, 2026, and is solely responsible for the information contained therein.